BACKGROUND: The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV. METHODS: The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose. RESULTS: In total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3. CONCLUSIONS:Sabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups. CLINICAL TRIALS REGISTRATION: NCT01056705.
RCT Entities:
BACKGROUND: The production of Sabin inactivated poliovirus vaccine (IPV) can reduce biosafety requirements in the posteradication/post-oral poliovirus vaccine (OPV) era. We conducted a phase II, randomized, positive-controlled trial to assess the safety and immunogenicity of Sabin IPV. METHODS: The test groups (A, B, and C) received 3 doses of high, middle, and low D antigen (D Ag) of Sabin IPV at ages 2, 3, and 4 months, respectively. Infants in 2 control groups, group D and group E, received 3 doses of trivalent OPV and conventional IPV (cIPV), respectively, on the same schedule as that of groups A, B, and C. Serum samples were collected before and 30 days after the administration of the third dose. RESULTS: In total, 500 infants were randomly assigned to 5 groups, and 449 infants completed the vaccine series. No serious adverse events were associated with vaccinations. After 3 doses, the seroconversion rates in groups A, B, C, D, and E were 100%, 97.8%, 96.6%, 100%, and 90.1%, respectively, for type 1 poliovirus; 97.7%, 95.7%, 78.7%, 100%, and 90.1%, respectively, for type 2; and 98.8%, 98.9%, 93.3%, 100%, and 97.8%, respectively, for type 3. CONCLUSIONS:Sabin IPV has good safety characteristics. The seroconversion rates for type 1 poliovirus (most appropriate concentration, 15 D Ag units [DU]), type 2 (32 DU), and type 3 (45 DU) Sabin IPV were similar to those of the OPV and cIPV control groups. CLINICAL TRIALS REGISTRATION: NCT01056705.
Authors: Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi Journal: Risk Anal Date: 2013-03-05 Impact factor: 4.000
Authors: Jessica A White; Jeremy S Blum; Nancy A Hosken; Joshua O Marshak; Lauren Duncan; Changcheng Zhu; Elizabeth B Norton; John D Clements; David M Koelle; Dexiang Chen; William C Weldon; M Steven Oberste; Manjari Lal Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Yvonne E Thomassen; Aart G van 't Oever; Monique G C T van Oijen; René H Wijffels; Leo A van der Pol; Wilfried A M Bakker Journal: PLoS One Date: 2013-12-12 Impact factor: 3.240
Authors: Barbara P Sanders; Isabel de Los Rios Oakes; Vladimir van Hoek; Viki Bockstal; Tobias Kamphuis; Taco G Uil; Yutong Song; Gillian Cooper; Laura E Crawt; Javier Martín; Roland Zahn; John Lewis; Eckard Wimmer; Jerome H H V Custers; Hanneke Schuitemaker; Jeronimo Cello; Diana Edo-Matas Journal: PLoS Pathog Date: 2016-03-31 Impact factor: 6.823